IDM Pharma Reports 2008 Financi...(year ended periods were to record the ch...)

The foreign exchange gain, which results from changes in the value of the dollar versus the Euro on the dollar denominated inter-company loan between the Company's subsidiaries, was $0.1 million in the fourth quarter of 2008, compared to a foreign exchange loss of $0.4 million in the fourth quarter of 2007. This foreign exchange loss was $0.1 million in the year ended December 31, 2008, compared to $1.7 million in the year ended December 31, 2007.

Net loss for the fourth quarter of 2008 was $1.9 million, or $0.07 per basic and diluted share, compared to a net loss of $2.7 million, or $0.11 per share in the corresponding period in 2007. Net loss for the year ended December 31, 2008 was $18.6 million, or $0.74 per basic and diluted loss per share compared to a net loss of $18.4 million, or $0.87 per share in the year ended December 31, 2007.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the Company's ability to deliver near-term value to its stockholders, completion of pre-launch activities and marketing of MEPACT in the EU, the timeframe in which the Compa
'/>"/>